Nabumetone dispersible tablets

This product is a non-acidic non-steroidal anti-inflammatory drug, which is rapidly metabolized to 6-methoxy-2-naphthylacetic acid (6-MNA) in the liver and has antipyretic, analgesic and anti-inflammatory effects. 1 The anti-inflammatory, analgesic and antipyretic effects are related to the fact that the active metabolites of cabutimetone inhibit the synthesis of prostaglandins in inflammatory tissues. 2 Little effect on gastric mucosa: This product is a non-acidic, non-ionic prodrug, which has no obvious local direct effect on the gastric mucosa during the absorption process; at the same time, this product has little inhibitory effect on the physiological cyclooxygenase of the gastric mucosa. Therefore, the incidence of gastrointestinal mucosal erosion and bleeding caused by this product is low. 3 No effect on bleeding and coagulation: This product has no effect on the platelet aggregation induced in vitro in blood samples of healthy volunteers. There were no significant changes in bleeding time and coagulation tests.

The main ingredient's generic name is nabumetone and its chemical name is: 4-(6-methoxy-2-naphthyl)-2-butanone.

This product is white tablets.

It is suitable for osteoarthritis, rheumatoid arthritis and similar symptoms requiring anti-inflammatory treatment.

Adults: Oral, 1g (2 tablets) once a day, before bedtime. Adults weighing less than 50kg can start with 0.5g daily, and gradually increase to the effective dose. For severe or persistent symptoms, or acute exacerbations, an additional 500mg-1g can be added, administered in the early morning.

1. Gastrointestinal tract: nausea, vomiting, indigestion, diarrhea, abdominal pain and constipation, about 1% to 3%. Upper gastrointestinal bleeding, about 0.7%. In cases using this product, the incidence of ulcers was 0.1% in the short-term treatment group (6 weeks to 6 months) and 0.95% in the long-term treatment group (8 years). The incidence of diarrhea increased with daily oral administration of 2g of nabumetone. 2. Nervous system: manifestations include headache, dizziness, tinnitus, sweating, insomnia, drowsiness, tension and dreaminess, with an incidence of less than 1.5%. 3. Skin: rash and itching, about 2.1%, edema, about 1.1%. 4. Rare or occasional adverse reactions include jaundice, abnormal liver function, anxiety, depression, paresthesia, tremor, dizziness, bullous rash, urticaria, dyspnea, asthma, allergic pneumonia, proteinuria, hematuria and vascular

1. It is contraindicated in patients with active peptic ulcer, severe liver damage (e.g., cirrhosis), and allergies to nabumetone and other nonsteroidal anti-inflammatory drugs. 2. Use during pregnancy and lactation: Animal studies have shown no potential for teratogenicity. Like other compounds, maternal toxicity can be seen in animals at sufficiently high doses, and embryonic signs have been recorded (the dose in rabbit studies was 300 mg/kg). High-dose studies in rats (320 mg/kg) can delay delivery, which is believed to be due to the inhibition of prostaglandin synthesis. 3. Nabumetone's active metabolites can be found in mammalian milk, and its safety for use in pregnant women has not been determined. Naphthalene

Precautions for children: Not recommended for children. Precautions for pregnancy and lactation: Not recommended for pregnant and lactating women. Precautions for the elderly: When the elderly use this product, generally no more than 1g (2 tablets) per day, usually 0.5g (1 tablet) will achieve satisfactory results.

1. The absorption rate of this product is not affected by the combined use of aluminum hydroxide gel, aspirin or acetaminophen. However, it is generally not recommended to use two or more non-steroidal anti-inflammatory drugs at the same time. 2. There is no interaction between this product and the anticoagulant warfarin in healthy volunteers. However, there is no data on the combined use of these two drugs in patients. 3. The dose should be appropriately reduced when this product is used in combination with acetyl anticonvulsants and sulfonylurea hypoglycemic drugs. Overdose: When symptoms of poisoning occur due to overdose, gastric lavage or vomiting should be performed in time, and more than 60g of activated carbon should be taken orally to absorb the residual drugs in the digestive tract, and appropriate symptomatic and supportive therapy should be given.

Keep away from light and store in a sealed container.

0.5g

18 months

Lingyuan Pharmaceutical Co., Ltd.

• Founded in:

  2017-09-01

• Address:

  Lingyuan Pharmaceutical, No. 17, Chang'an Road, Jinjiang Economic Development Zone (Wuliyuan), Quanzhou City, Fujian Province

• Tax NO.:

  91350582MA2YJ8736E

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view